Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/35429
Title: High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy.
Austin Authors: Hume, Simon J;Wong, Danny K;Yuen, Man-Fung;Jackson, Kathy;Bonanzinga, Sara;Vogrin, Sara;Hall, Samuel A L;Burns, Gareth S;Desmond, Paul V;Sundararajan, Vijaya;Ratnam, Dilip;Levy, Miriam T;Lubel, John S;Nicoll, Amanda J;Strasser, Simone I;Sievert, William;Ngu, Meng C;Sinclair, Marie ;Meredith, Christopher;Matthews, Gail;Revill, Peter A;Littlejohn, Margaret;Bowden, Scott;Visvanathan, Kumar;Holmes, Jacinta A;Thompson, Alexander J
Affiliation: St Vincent's Hospital Melbourne, Fitrozy, Victoria, Australia.;Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.;Victorian Infectious Diseases Reference Laboratory, Department of Infectious Diseases, Royal Melbourne Hospital, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR, China.
Victorian Infectious Diseases Reference Laboratory, Department of Infectious Diseases, Royal Melbourne Hospital, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.
Western Health, Melbourne, Australia.
St Vincent's Hospital Melbourne, Fitrozy, Victoria, Australia.;Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.
Monash Health, Melbourne, Victoria, Australia.
Liverpool Hospital, Sydney, New South Wales, Australia.
Alfred Health, Melbourne, Victoria, Australia.
Eastern Health, Melbourne, Victoria, Australia.
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Monash Health, Melbourne, Victoria, Australia.
Concord Hospital, Sydney, New South Wales, Australia.
Austin Health
Bankstown-Lindcombe Hospital, Sydney, New South Wales, Australia.
St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
The Peter Doherty Institute
Victorian Infectious Diseases Reference Laboratory, Department of Infectious Diseases, Royal Melbourne Hospital, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Issue Date: Oct-2024
Date: 2024
Publication information: Liver International : Official Journal of the International Association for the Study of the Liver 2024-10; 44(10)
Abstract: Accurate biomarkers to predict outcomes following discontinuation of nucleos(t)ide analogue (NA) therapy are needed. We evaluated serum hepatitis B core-related antigen (HBcrAg) level as a biomarker for predicting outcomes after NA discontinuation. Patients with HBeAg-negative chronic hepatitis B (CHB) without cirrhosis were enrolled in a prospective trial evaluating clinical outcomes until 96 weeks after NA discontinuation. End of treatment (EOT) and off-treatment levels of serum HBcrAg, HBsAg, HBV RNA and HBV DNA were used to predict key clinical outcomes including hepatitis flare (ALT ≥5 × ULN and HBV DNA > 2000 IU/mL). The SCALE-B score was calculated for the purposes of model validation. HBcrAg was tested amongst 65 participants. The median age was 54 years, 54% were male and 83% were Asian. HBcrAg was detectable in 86% patients. HBcrAg level ≥4 log U/mL at EOT was predictive of hepatitis flare [8/10 (80%) vs. 17/55 (31%), p = .001]. The presence of either HBcrAg ≥4 log U/mL or detectable HBV RNA at EOT predicted for both biochemical relapse and hepatitis flare. The SCALE-B model at EOT predicted for virological relapse, biochemical relapse, hepatitis flare and HBsAg loss in this cohort. An increase in the serum HBcrAg level off-treatment was also associated with hepatitis flare. No participant with EOT HBcrAg level ≥4 log U/mL achieved HBsAg loss. High levels of serum HBcrAg predict for hepatitis flare after stopping NA therapy and low likelihood of HBsAg loss at week 96. People with high levels of serum HBcrAg are not suitable candidates for NA discontinuation.
URI: https://ahro.austin.org.au/austinjspui/handle/1/35429
DOI: 10.1111/liv.16029
ORCID: 0009-0002-0435-6138
0000-0001-7985-7725
0000-0001-6374-1525
0000-0003-0657-3048
Journal: Liver International : Official Journal of the International Association for the Study of the Liver
PubMed URL: 39007640
ISSN: 1478-3231
Type: Journal Article
Subjects: biomarker
hepatitis B
hepatitis B core‐related antigen
hepatitis flare
nucleot(s)ide analogue
nucleot(s)ide analogue discontinuation
Appears in Collections:Journal articles

Show full item record

Page view(s)

20
checked on Dec 4, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.